497 related articles for article (PubMed ID: 30151994)
1. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
2. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
[TBL] [Abstract][Full Text] [Related]
3. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
4. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
[TBL] [Abstract][Full Text] [Related]
5. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
7. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
[TBL] [Abstract][Full Text] [Related]
11. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies.
Sezgin O; Aydın MK; Özdemir AA; Kanık AE
Turk J Gastroenterol; 2019 May; 30(5):420-435. PubMed ID: 31060997
[TBL] [Abstract][Full Text] [Related]
12. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
13. The safety and effectiveness of vonoprazan-based
Ashida K; Honda Y; Sanada K; Takemura Y; Sakamoto S
Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
[No Abstract] [Full Text] [Related]
14. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Nagahara A; Miwa H; Ogawa K; Kurosawa A; Ohkura R; Iida N; Sato N
Helicobacter; 2000 Jun; 5(2):88-93. PubMed ID: 10849057
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K
Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
[TBL] [Abstract][Full Text] [Related]
17. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
[TBL] [Abstract][Full Text] [Related]
20. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
